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Abstract Subacute cutaneous lupus erythematosus
(SCLE) is an autoimmune disease that may be induced by
proton pump inhibitors (PPIs) in at-risk populations. The
US FDA does not recognize SCLE as an adverse event
associated with PPIs. We queried the FDA Adverse Event
Reporting System database, which contains adverse event
case reports submitted by the public as well as by industry,
and analyzed the data to quantify passive pharmacovigi-
lance signals for SCLE associated with PPIs. A dispro-
portionality analysis of the signals yielded a significant
association between SCLE and PPIs. Discontinuation of
PPI resulted in remission, with PPI re-challenge causing
SCLE to reoccur. A follow-up analysis also yielded a
significant association between SCLE and H2 receptor
antagonists. We conducted a brief literature survey of
published case reports and studies to discern the validity of
PPI-induced SCLE signals. Healthcare prescribers and
patients should be made aware that SCLE can be induced
by PPIs. In such cases, PPIs should be discontinued and
alternative clinical treatment sought. Regulatory bodies
such as the FDA should incorporate the adverse reaction in
PPI prescription labels.
Key Points
Pharmacovigilance analysis of the US FDA Adverse
Event Reporting System (FAERS) database provided
a signal of association between subacute cutaneous
lupus erythematosus and proton pump inhibitors.
Statistical analysis and published case reports
confirmed the association.
Proton pump inhibitors should be discontinued if
subacute cutaneous lupus erythematosus symptoms
occur.
1 Introduction
The rate of autoimmune disorders is increasing exponen-
tially in the Western world. In the USA, the prevalence of
autoimmune disease has risen from 3 % in the 1960s to
9 % in 2009 [1]. One of the autoimmune diseases is lupus
erythematosus, in which a hyperactive immune system
attacks its own tissue cells. Subacute cutaneous lupus
erythematosus (SCLE) is a distinct subset of cutaneous
lupus erythematosus and presents clinically with non-
scarring, erythematous, annular polycyclic or papulosqua-
mous cutaneous eruptions in sun-exposed areas [2]. While
SCLE can be idiopathic or drug induced, they are generally
immunologically, histopathologically, and clinically
indistinguishable. Thiazides, terbinafine, calcium channel
blockers, angiotensin-converting enzyme inhibitors
(ACEIs), tumor necrosis factor (TNF)-a inhibitors, and
chemotherapeutic agents have all been implicated as sus-
pected or probable causes of drug-induced SCLE. Proton
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pump inhibitors (PPIs) have also been associated with and
may induce SCLE.
The US FDA does not recognize SCLE as a PPI-asso-
ciated adverse event, and FDA-approved prescribing
information for PPIs does not include SCLE as an associ-
ated adverse event. In this article, we analyze passive
pharmacovigilance signals for PPI-associated SCLE and
support our findings with published case reports and case–
control studies. PPIs as a class work by inhibiting gastric
acid secretion in the gastric lumen. They inhibit the K?/
H? ATPase pump in the lining of gastric parietal cells [3].
This causes a reduction in acid secretion because hydrogen
ions are unable to be transported to the gastric surface. PPIs
are used to treat conditions such as dyspepsia and gas-
troesophageal reflux disease (GERD). This group of inhi-
bitors comprises some of the World Health Organization
(WHO) ‘‘World’s essential medications’’ such as omepra-
zole, pantoprazole, and lansoprazole.
2 Methods
2.1 Data Collection
The FDA Adverse Event Reporting System (FAERS)
database collects spontaneous reports of adverse events and
medication errors involving human drugs and therapeutic
biological products. The information is publically available
as computerized quarterly data reports on the FAERS
website [4]. Adverse event and medication error reports are
submitted to the FDA by drug manufacturers, healthcare
professionals (e.g., physicians, pharmacists, and nurses),
and consumers (e.g., patients, family members, and law-
yers). The original Adverse Event Reporting System
(AERS) was designed in 1969 to support the FDA’s post-
marketing safety surveillance program for drug and thera-
peutic biologic products. It was replaced by FAERS on 10
September 2012, and the database now contains over 9
million reports of adverse events from 1969 to the present
day. Since the last major revision, in 1997, reporting has
markedly increased. The quarterly data files, available in
ASCII or SGML formats, include demographic and
administrative information; drug, reaction, and patient
outcome information from the reports; and information on
the source of the reports [4].
The adverse events data for the present analysis were
obtained from the FAERS website for the period 1 July
2013 to 30 June 2015. The data tables ‘‘Demographics,’’
‘‘Drugs,’’ ‘‘Indications,’’ ‘‘Outcomes, Reactions,’’ ‘‘Report
Source,’’ and ‘‘Therapy’’ were downloaded and imported
into SQL Server (Microsoft SQL Server 2015); we then
combined the files using primary key and foreign keys. The
resulting tables were cleaned and duplicates removed. The
data were queried using SQL queries.
2.2 Adverse Event and Exposure Drug
We investigated the adverse event ‘‘subacute cutaneous
lupus erythematosus’’ and the drug class PPIs as being
associated with SCLE. The PPI class was defined as
comprising any of the following drugs: esomeprazole,
dexlansoprazole, omeprazole, lansoprazole, pantoprazole,
or rabeprazole, singularly or in combination.
2.3 Analysis
Disproportionality analysis can be used to identify statis-
tical associations between products and events in their
respective safety report databases. Such analysis compares
the observed count for a product–event combination with
an ‘‘expected’’ count. Unexpectedly high reporting asso-
ciations ‘‘signal’’ that there may be a causal association
between the particular adverse event and the product. This
analysis can also identify increased reporting rates for low
frequency events.
We used disproportionality analysis to quantify phar-
macovigilance signals in FAERS to provide a picture of the
drug-related risk. The association between the adverse
event and the drugs of interest was evaluated using the Chi
squared (v2) value with Yates correction, with values[4
considered statistically significant. We also calculated
measurements of disproportionality (observed–expected
ratios): relative reporting ratio (RRR), proportional
reporting ratio (PRR), and reporting odds ratio (ROR), and
their 95 % confidence intervals. Generally, the higher the
ratios, the more likely the association between drug(s) and
adverse event(s). According to the criteria of Evans et al.
[5], if (number of events C3, v2 C 4, and PRR C 2), the
combination of drug(s) and adverse event(s) is considered
‘‘likely’’ to be an adverse reaction.
3 Results
3.1 Analysis Results
A total of 220 cases listing SCLE as an adverse event were
reported during the 2-year period (third quarter of 2013 to
second quarter of 2015) with the use of any drug. Of these,
190 were reported by healthcare professionals and four by
consumers; none were reported by lawyers. The source for
the remaining 26 was missing from the database. Table 1
summarizes the major drug classes reported to have been
associated with SCLE during the period, and Table 2
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presents the demographics of the patients for whom the
adverse events were reported.
The query in the SQL data tables identified that more
than half (120) of the 220 SCLE adverse events were
associated with PPIs. Of the 120 cases associated with
PPIs, 95 were reported by healthcare professions and two
by consumers; none were reported by lawyers. The source
for the remaining 24 was missing from the database. Of the
120 adverse events, 95 % were coded as serious, with death
reported as an outcome in 4.2 %. PPIs were identified as
the ‘‘primary suspect’’ drug in all 120 adverse events.
Table 3 presents a 2 9 2 table of the queried results; v2
with Yates correction was 1874.74.
Table 4 presents the disproportionality ratios. A com-
parison of the results of the passive pharmacovigilance
analysis using FAERS data (n = 120; v2 = 1874.74,
PRR = 36.64 [95 % CI 28.10–47.77]) and Evans et al. [5]
criteria (n C 3, v2 C 4, PRR C2) indicates that SCLE is
statistically significantly associated with PPIs.
Of the 120 PPI-associated SCLE cases, 68 reports
indicate the drug was withdrawn after the event; no report
indicated a drug reduction, and only one report indicated
that drug dose remained unchanged. The other 51 cases
reported no action or ‘‘unknown.’’ Of the 120 PPI-induced
SCLE cases, only nine were reported to have been followed
longitudinally. All nine were reported to have reoccurred
on re-administration of the drug.
We subsequently stratified the data by sex and obtained
the corresponding disproportionality results. Table 3 pre-
sents a 2 9 2 table of the queried stratified results, and
Table 4 presents the corresponding disproportionality
ratios. The stratified results indicate that SCLE is statisti-
cally significantly associated with PPIs as an adverse event
in women (n = 97; v2 = 1591.27; PRR = 40.59 [95 % CI
29.97–54.99]). A significant association is also seen in
men, but to a lesser extent (n = 9; v2 = 61.72;
PRR = 13.85 [95 % CI 6.18–31.07]).
When SCLE occurs and the PPI is discontinued but the
patient still requires acid-suppression medication, one
option is to prescribe H2 receptor antagonists such as
cimetidine, famotidine, nizatidine, or ranitidine. We could
not identify via the FAERS data whether an H2 receptor
antagonist was started after a PPI was discontinued, and the
ensuing outcome of that switch on SCLE. However, we did
analyze FAERS data during the same time period to check
for any independent association between SCLE and H2
Table 1 The top ten drug classes associated with subacute cutaneous
lupus erythematosus reported in the US FDA Adverse Event
Reporting System database between 1 July 2013 and 30 June 2015,
stratified by drug class




4 Thiazide diuretics 25
5 ACEI/ARB 22
6 Thyroid medications 20
7 Aspirin 16
8 Beta blocker 15
9 Benzodiazepine 15
10 Stool softener 13
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin
receptor blocker, PPI proton pump inhibitor, SCLE subacute cuta-
neous lupus erythematosus
Table 2 Demographics of patients with subacute cutaneous lupus erythematosus reported in the US FDA Adverse Event Reporting System
database between 1 July 2013 and 30 June 2015
Characteristic Total (n = 220) Associated with PPI (n = 120) Associated with other drugs (n = 100)
Sexa
Male 26 (11.8) 9 (7.5) 17 (17.0)
Female 170 (77.3) 97 (80.8) 73 (73.0)
Missing 24 (10.9) 14 (11.7) 10 (10.0)
Age (years)
\25 10 (4.5) 10 (8.3) 0 (0)
C25 and\50 50 (22.7) 25 (20.8) 25 (25.0)
C50 and\70 71 (32.3) 44 (36.7) 27 (27.0)
C70 and\86 56 (25.5) 19 (15.8) 37 (37.0)
Missing 33 (15.0) 22 (18.3) 11 (11.0)
Mortality 7 (3.2) 5 (4.2) 2 (2.0)
Data are presented as n (%)
PPI proton pump inhibitor
a Fisher’s exact test (PPI and ‘other drugs’ vs. ‘male’ and ‘female’: p = 0.0269 [one tailed])
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receptor antagonists (Tables 5, 6). The results indicate that
SCLE is also significantly associated with H2 receptor
antagonists, but to a much smaller extent (n = 5;
v2 = 7.29; PRR = 3.74 [95 % CI 1.54–9.07]) than with
PPIs.
3.2 Supporting Literature
We conducted a brief review of the literature relating to
PPI-associated SCLE. We searched PubMed for published
studies (2000–2015) [6] to discern the validity of passive
pharmacovigilance. The literature studies reviewed are
broadly classified as clinical case reports, retrospective
studies, and case–control studies.
3.2.1 Clinical Case Reports
We identified 22 clinical case reports from 21 patients
(Table 7). The mean patient age was 58.33 years (range
30–85), and 20 of the 21 patients were female. One patient
was pregnant when she experienced the adverse reaction.
The presence of antinuclear antibodies, including anti-Ro/
SSA antibodies and anti-La/SSB antibodies, in blood
serum can be used to diagnose autoimmune disorders.
Antinuclear antibodies, positive anti-Ro/SSA antibodies,
and positive anti-La/SSB antibodies were found in 90, 90,
and 36 % of tested patients at the time of the rash,
respectively. The incubation period was in the range of
3 days to 5 months (mean 5 weeks), and the resolution
period was in the range of a few days to 4 months (mean
4.33 weeks) after the discontinuation of the PPI. SCLE
recurred in two patients with PPI re-challenge and resolved
after drug cessation. Two patients in whom the PPI was not
stopped had active SCLE up to their deaths (death reported
as due to other causes).
3.2.2 Chart Review
Sandholdt et al. [7] reported a retrospective medical
chart review of patients with SCLE carried out at Odene
University Hospital, Denmark. They identified 727 medical
records with an International Statistical Classification of
Diseases and Related Health Problems, tenth revision
(ICD-10) diagnosis code of lupus erythematosus, 429 of
which had confirmed cutaneous lupus erythematosus. In
Table 3 2 9 2 Contingency tables for reported proton pump inhi-
bitor-associated subacute cutaneous lupus erythematosus
Sex PPIs All other drugs Total
All
SCLE 120 100 220
All other AEs 56,604 1,732,098 1,788,702
Total AEs 56,724 1,732,198 1,788,922
v2 with Yates correction: 1874.74
Female
SCLE 97 73 170
All other AEs 31,546 966,585 998,131
Total AEs 31,643 966,658 998,301
v2 with Yates correction: 1591.27
Male
SCLE 9 17 26
All other AEs 22,810 597,071 619,881
Total AEs 22,819 597,088 619,907
v2 with Yates correction: 61.72
AE adverse event, PPI proton pump inhibitor, SCLE subacute cuta-
neous lupus erythematosus
Table 4 Disproportionality analysis results for reported proton pump
inhibitor-associated subacute cutaneous lupus erythematosus
Sex Measure Ratio (95 % CI)
All Proportional reporting ratio 36.64 (28.10–47.77)
Relative odds ratio 36.72 (28.16–47.89)
Relative reporting ratio 17.20 (13.77–21.48)
Female Proportional reporting ratio 40.59 (29.97–54.99)
Relative odds ratio 40.71 (30.05–55.17)
Relative reporting ratio 18.00 (14.03–23.09)
Male Proportional reporting ratio 13.85 (6.18–31.07)
Relative odds ratio 13.86 (6.18–31.09)
Relative reporting ratio 9.40 (4.41–20.07)
CI confidence interval
Table 5 2 9 2 Contingency table for reported H2 receptor antago-
nist-associated subacute cutaneous lupus erythematosus
H2 receptor
antagonists
All other drugs Total
SCLE 5 215 220
All other AEs 11,057 1,777,645 1,788,702
Total AEs 11,062 1,777,860 1,788,922
v2 with Yates correction: 7.29
AE adverse event, SCLE subacute cutaneous lupus erythematosus
Table 6 Disproportionality analysis results for reported H2 receptor
antagonist-associated subacute cutaneous lupus erythematosus
Measure Ratio (95 % CI)
Proportional reporting ratio 3.74 (1.54–9.07)
Relative odds ratio 3.74 (1.54–9.08)
Relative reporting ratio 3.68 (1.52–8.92)






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































total, 24 patients with 30 episodes of PPI-induced SCLE
were identified; 19 patients with 24 episodes were identi-
fied for the first time [7], and the rest were identified earlier
in clinical case reports [8]. The incubation period was in
the range of 1 week to 3.5 years (mean 8 months) and the
resolution period was in the range of 4 weeks to 8 months
(mean 3 months) after PPI discontinuation. Antinuclear
antibodies, positive anti-Ro/SSA antibodies, positive anti-
La/SSB antibodies, and anti-histone antibodies were found
in 61, 73, 33, and 8 % of tested patients at the time of rash,
respectively. Furthermore, in this cohort, two patients in
whom PPIs were not discontinued had active SCLE up to
their death.
3.2.3 Case–Control Study
We only identified one case–control study that evaluated
the association between exposure to suspected drugs and
subsequent diagnosis of SCLE [2]. The study was a pop-
ulation-based matched case–control study in which 234
cases of SCLE in Sweden (2006–2009) derived from the
National Patient Register were identified. The control
group was matched on a 1:10 ratio (n = 2311) for sex, age,
and country of residence. Of the 234 cases, 66 were
identified as being associated with antithrombotics, fol-
lowed by PPIs (n = 65), non-steroidal anti-inflammatory
drugs (NSAIDs) (n = 51), and beta-blockers (n = 50).
Among these drug groups, the odds ratios (ORs) were
significant for PPIs (OR 2.9; 95 % CI 2.0–4.0),
antithrombotics (OR 2.2; 95 % CI 1.5–3.2), and NSAIDs
(OR 1.6; 95 % CI 1.1–2.2).
4 Discussion
4.1 Limitations of Analysis
FAERS provides a passive pharmacovigilance risk signal
and indicates associations. However, there is no certainty
that the reported event (adverse event) was actually
induced or caused by the drug product. Although the dis-
proportionality analysis quantifies the signal to provide a
picture of the drug-related risk, it in itself is generally
insufficient to prove a causal relationship. The analysis,
coupled with multiple sources of data such as clinical case
reports and case–control studies, can be helpful in inferring
the causal relationship and recommending and modifying
clinical practice guidelines. Regulatory actions in response
to emerging drug safety concerns often depend on an
accurate assessment of risks using multiple data sources as
well as consideration of overall benefits and risks of the
agent [9]. Therefore, this study should be placed in context
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Further, FDA does not receive reports for every adverse
event or medication error that occurs with a product.
Identical or similar reports may be submitted by a health-
care professional and the patient or lawyer. Many factors
can influence whether or not an event will be reported, such
as the time a product has been marketed and publicity
about an event. Therefore, FAERS data cannot be used to
calculate the incidence of an adverse event or medication
error within a population [4]. Well designed, randomized,
prospective, large-scale, and long-term clinical trials are
the best way to assess the relationship between an adverse
event and a drug. On the other hand, while post-marketing
vigilance such as FAERS has a limited ability to establish
causal relationships, it does have advantages in terms of
being able to identify signals in real-world situations with
multi-drug regimens, reactivations of adverse events after
cessation of therapy, and global differences in the occur-
rence of adverse events.
4.2 General Discussion
Over the past decade, an increasing number of drugs in
different classes have been implicated as triggers for drug-
induced SCLE. Antihypertensives (including calcium
channel blockers, diuretics, beta-blockers, and ACEIs),
antifungals, chemotherapeutics, antihistamines,
immunomodulators, antiepileptics, statins, NSAIDs, hor-
mone-altering drugs, and ultraviolet therapy have all been
reported as inducing SCLE. One possibility is that many
drugs trigger SCLE by inducing a photosensitive state.
Such a state might then nonspecifically induce SCLE skin
lesions via an isomorphic response (Ko¨bner response) in an
individual who is immunogenetically predisposed to
developing SCLE [10].
In our analysis, 120 of the 220 SCLE cases reported in
FAERS during the 2-year study period were associated
with PPIs. The passive pharmacovigilance data indicated
that PPIs were statistically significantly associated with
lupus. However, it is possible that this is not a side effect of
PPI but that a downstream mechanism is causing these
symptoms. To explore this further, we compared PPIs and
H2 receptor antagonists, an alternative to PPIs. PPIs work
by inhibiting the K?/H? ATPase pump in the lining of the
gastric parietal cells. This reduces acid secretion because
the hydrogen ions are unable to be transported to the gastric
surface. H2 receptor antagonists work in a similar manner
and have the same end effect: inhibition of the proton
pump. However, H2 receptor antagonist drugs initially
block the histamine channel. This channel downregulates
the proton pump via the vagus nerve. Since H2 receptors
also statistically significantly cause this phenomenon, it is
likely that the proton pump induces SCLE instead of SCLE
being a direct side effect of PPIs.
The statistically significant findings from our analysis of
FAERS signals indicate the signal generated by FAERS is
not false positive and that the SCLE is induced by PPIs.
This cause–effect relationship is reinforced by the recur-
rence of SCLE upon re-challenge with the PPI in all nine
longitudinally followed FAERS cases. Similarly, in the
published clinical case reports where cessation of PPI
treatment resulted in remission, a re-challenge again
resulted in SCLE. PPI re-challenge caused SCLE to re-
emerge with a shorter incubation period, reinforcing the
relationship and indicating that an earlier episode of SCLE
predisposes the patient to subsequent SCLE flare-ups.
At the Pharmacovigilance Risk Assessment Committee
meeting in July 2015, the European Medicines Agency
(EMA) issued a warning that SCLE is likely to be a class
effect for PPIs [11]. The warning further states that SCLE
after previous treatment with a PPI may increase the risk of
SCLE with other PPIs. In September 2015, the UK
Medicines and Healthcare products Regulatory Agency
(MHRA) [12] stated that PPIs are associated with very
infrequent cases of SCLE. These reports by the EMA and
MHRA were based on the global safety databases of
Takeda, Janssen/Eisai, and AstraZeneca, as well as com-
ments received from marketing authorization holders. The
FDA-approved PPI labels do not mention the adverse effect
at all. The FDA should consider adding SCLE as an
adverse event to PPI prescription labels. This can be sup-
plemented with a Medication Guide for patients, containing
adverse event warnings and describing alternatives to PPIs.
4.3 Clinical Practice Guidelines
and Recommendations
Risk factors for developing SCLE include being a woman
of child-bearing age, periods of female hormone changes,
previous drug allergies or previous SCLE episodes, sun-
reactive skin, exposure to ultraviolet radiation, and family
history. When prescribing PPIs, especially to at-risk
patients, the prescriber or the healthcare provider should
ensure the patient is aware of the possibility of skin rash
and SCLE and the associated symptoms. Patients should be
advised to take protective measures against sun exposure,
especially for bare skin. Non-allergic sunscreens or
antioxidants may be applied to the skin if sun exposure
cannot be avoided. If lesions occur, especially in sun-ex-
posed areas of the skin, and if they are accompanied by
arthralgia, the patient should seek medical help promptly.
If the healthcare professional suspects SCLE and the
patient is receiving any PPIs, the PPI should be discon-
tinued immediately. The patient should be medically fol-
lowed to observe remission of SCLE symptoms. If
warranted, the patient can be treated with hydroxychloro-
quine, topical steroids, topical tacrolimus, and prednisolone
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[10]. For acid reflux treatment, the patient may start one of
the following: alginate and bicarbonate sodium [13],
magnesium carbonate, magnesium trisilicate, and magne-
sium hydroxide/milk of magnesia [14]. PPIs should not be
restarted, even if acid reflux symptoms do not subside, as
they may induce a relapse of SCLE. H2 receptor antago-
nists may be initiated under medical supervision and the
patient followed-up for any SCLE relapse. If neither of
these therapies alleviates the symptoms, nissen fundopli-
cation is also an option to consider. Regulatory bodies such
as FDA should incorporate the drug-induced adverse
reaction of SCLE in prescription labels of PPIs, especially
for at-risk populations.
5 Conclusion
Analysis of passive pharmacovigilance data confirms a
statistically significant association between SCLE and
PPIs. SCLE can be induced by PPIs, and patients and
prescribers should be made aware of the association
between the two. An increased awareness among pre-
scribers and patients can lead to withdrawal of the
offending PPI and subsequent remission of the lupus ery-
thematosus, decreasing the morbidity of the patients.
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